Quest Diagnostics Inc. (DGX): Price and Financial Metrics

Quest Diagnostics Inc. (DGX): $133.11

2.05 (+1.56%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

B

DGX Price/Volume Stats

Current price $133.11 52-week high $148.62
Prev. close $131.06 52-week low $119.59
Day low $131.18 Volume 888,000
Day high $133.41 Avg. volume 1,053,229
50-day MA $127.84 Dividend yield 2.2%
200-day MA $132.02 Market Cap 14.78B

DGX Stock Price Chart Interactive Chart >

DGX POWR Grades

  • DGX scores best on the Quality dimension, with a Quality rank ahead of 82.77% of US stocks.
  • DGX's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
  • DGX ranks lowest in Momentum; there it ranks in the 26th percentile.

DGX Stock Summary

  • QUEST DIAGNOSTICS INC's market capitalization of $15,704,920,381 is ahead of 87.16% of US-listed equities.
  • As for revenue growth, note that DGX's revenue has grown -9.69% over the past 12 months; that beats the revenue growth of merely 22.59% of US companies in our set.
  • In terms of volatility of its share price, DGX is more volatile than merely 4.12% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to QUEST DIAGNOSTICS INC are PKG, BEN, BRO, COTY, and HRL.
  • DGX's SEC filings can be seen here. And to visit QUEST DIAGNOSTICS INC's official web site, go to www.questdiagnostics.com.

DGX Valuation Summary

  • In comparison to the median Healthcare stock, DGX's price/sales ratio is 22.73% lower, now standing at 1.7.
  • Over the past 243 months, DGX's price/earnings ratio has gone up 1.6.

Below are key valuation metrics over time for DGX.

Stock Date P/S P/B P/E EV/EBIT
DGX 2023-12-29 1.7 2.4 20.3 18.2
DGX 2023-12-28 1.7 2.4 20.3 18.2
DGX 2023-12-27 1.7 2.4 20.3 18.2
DGX 2023-12-26 1.7 2.4 20.2 18.1
DGX 2023-12-22 1.7 2.4 20.1 18.1
DGX 2023-12-21 1.6 2.4 20.0 18.1

DGX Growth Metrics

    Its 2 year revenue growth rate is now at 39.47%.
  • Its year over year net cashflow from operations growth rate is now at -20.37%.
  • Its 3 year revenue growth rate is now at 41.67%.
Over the past 34 months, DGX's revenue has gone up $2,226,000,000.

The table below shows DGX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 9,883 1,718 946
2022-09-30 10,294 1,865 1,235
2022-06-30 10,582 1,924 1,484
2022-03-31 10,679 1,982 1,881
2021-12-31 10,788 2,233 1,995
2021-09-30 11,046 2,293 2,184

DGX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DGX has a Quality Grade of B, ranking ahead of 93.32% of graded US stocks.
  • DGX's asset turnover comes in at 0.812 -- ranking 31st of 81 Healthcare stocks.
  • SSY, LH, and BIOC are the stocks whose asset turnover ratios are most correlated with DGX.

The table below shows DGX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.812 0.403 0.404
2021-06-30 0.805 0.412 0.417
2021-03-31 0.750 0.404 0.340
2020-12-31 0.709 0.385 0.277
2020-09-30 0.643 0.362 0.221
2020-06-30 0.604 0.334 0.162

DGX Price Target

For more insight on analysts targets of DGX, see our DGX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $157.67 Average Broker Recommendation 1.56 (Moderate Buy)

Quest Diagnostics Inc. (DGX) Company Bio


Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United StatesPuerto RicoMexico, and Brazil.  Quest also maintains collaborative agreements with various hospitals and clinics across the globe. (Source:Wikipedia)


DGX Latest News Stream


Event/Time News Detail
Loading, please wait...

DGX Latest Social Stream


Loading social stream, please wait...

View Full DGX Social Stream

Latest DGX News From Around the Web

Below are the latest news stories about QUEST DIAGNOSTICS INC that investors may wish to consider to help them evaluate DGX as an investment opportunity.

Quest Diagnostics to Speak at the 42nd Annual J.P. Morgan Healthcare Conference

Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information services, announced that Jim Davis, Chairman, CEO and President, and Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance, and the latest market developments and trends during a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024, at 6:45 p.m. Eastern Time.

Yahoo | December 21, 2023

Quest Diagnostics Names Yuri A. Fesko, M.D., Senior Vice President and Chief Medical Officer

Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced that Yuri A. Fesko, M.D., has been named senior vice president and chief medical officer (CMO), effective immediately.

Yahoo | December 20, 2023

Quest Diagnostics (DGX) Unveils the 88-Compound NPS Test Panel

Quest Diagnostics (DGX) launches the new 88-Compound NPS test panel to address the changing drug epidemic.

Yahoo | December 20, 2023

Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis

Relationship leverages Quest's sequencing and specimen collection expertise with Scipher's precision medicine technology SECAUCUS, NJ and WALTHAM, MA / ACCESSWIRE / December 19, 2023 / Quest Diagnostics (NYSE:DGX), the world's leading provider of ...

Yahoo | December 19, 2023

Quest Diagnostics Launches New 88-Compound Novel Psychoactive Substance Test Panel

Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today unveiled its new confirmatory testing service for novel psychoactive substances (NPS). The new panel, which tests for 88 compounds, covers a broad array of drug classes, such as designer opioids, designer benzodiazepines, designer stimulants, fentanyl analogs, synthetic cannabinoids, and other illicit additives. Two of these classes are rapidly accelerating America's overdose crisis: other illi

Yahoo | December 19, 2023

Read More 'DGX' Stories Here

DGX Price Returns

1-mo 5.93%
3-mo -2.95%
6-mo 10.45%
1-year -2.39%
3-year 9.88%
5-year 63.88%
YTD -2.95%
2023 -10.05%
2022 -7.80%
2021 47.86%
2020 14.11%
2019 31.13%

DGX Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full DGX Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!